Duration of the anti-androgen in men undergoing six months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death

IMPORTANCE: Whether adding an anti-androgen (AA) to a luteinizing hormone-releasing hormone agonist in the radiotherapeutic management of unfavorable-risk prostate cancer (PC) reduces the risk of all cause and PC-specific mortality (ACM and PCSM) among men within differing comorbidity subgroups is u...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Prostate Cancer Prostatic Dis
Päätekijät: Sanford, Nina N., Chen, Ming-Hui, Loffredo, Marian, Renshaw, Andrew, Kantoff, Philip W., D’Amico, Anthony V.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171772/
https://ncbi.nlm.nih.gov/pubmed/27824043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2016.53
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia